Tags

Type your tag names separated by a space and hit enter

Pharmacotherapy of Parkinson's disease.
Am J Hosp Pharm. 1977 May; 34(5):531-8.AJ

Abstract

The pathophysiology, anticholinergic therapy and dopaminergic therapy of Parkinson's disease are reviewed; an emphasis is placed on the structure and function of the basal ganglia because of their importance in understanding the pharmacotherapy of parkinsonism. The pharmacologic management of Parkinson's disease is limited primarily to manipulation of the dopamine-acetylcholine system. Levodopa, with or without a peripheral dopa decarboxylase inhibitor, is the current drug of choice in the management of idiopathic and postencephalitic Parkinson's disease. Modification of the serotonin-histamine system via the use of antihistamines may be useful in some patients. There are also many adjunctive agents which may be employed in combination with or in place of levodopa. Levodopa clearly has no place in the treatment of neuroleptic-induced Parkinson's disease; anticholinergics and antihistamines are the agents of choice.

Authors

No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

326045

Citation

Cohen, M M., and R T. Scheife. "Pharmacotherapy of Parkinson's Disease." American Journal of Hospital Pharmacy, vol. 34, no. 5, 1977, pp. 531-8.
Cohen MM, Scheife RT. Pharmacotherapy of Parkinson's disease. Am J Hosp Pharm. 1977;34(5):531-8.
Cohen, M. M., & Scheife, R. T. (1977). Pharmacotherapy of Parkinson's disease. American Journal of Hospital Pharmacy, 34(5), 531-8.
Cohen MM, Scheife RT. Pharmacotherapy of Parkinson's Disease. Am J Hosp Pharm. 1977;34(5):531-8. PubMed PMID: 326045.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacotherapy of Parkinson's disease. AU - Cohen,M M, AU - Scheife,R T, PY - 1977/5/1/pubmed PY - 1977/5/1/medline PY - 1977/5/1/entrez SP - 531 EP - 8 JF - American journal of hospital pharmacy JO - Am J Hosp Pharm VL - 34 IS - 5 N2 - The pathophysiology, anticholinergic therapy and dopaminergic therapy of Parkinson's disease are reviewed; an emphasis is placed on the structure and function of the basal ganglia because of their importance in understanding the pharmacotherapy of parkinsonism. The pharmacologic management of Parkinson's disease is limited primarily to manipulation of the dopamine-acetylcholine system. Levodopa, with or without a peripheral dopa decarboxylase inhibitor, is the current drug of choice in the management of idiopathic and postencephalitic Parkinson's disease. Modification of the serotonin-histamine system via the use of antihistamines may be useful in some patients. There are also many adjunctive agents which may be employed in combination with or in place of levodopa. Levodopa clearly has no place in the treatment of neuroleptic-induced Parkinson's disease; anticholinergics and antihistamines are the agents of choice. SN - 0002-9289 UR - https://www.unboundmedicine.com/medline/citation/326045/Pharmacotherapy_of_Parkinson's_disease_ L2 - https://medlineplus.gov/parkinsonsdisease.html DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.